Vizimpro

Chemical Namedacomitinib
Dosage FormTablet (oral; 15 mg, 30 mg, 45 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyPfizer
Approval Year2018

Indication

  • Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
Last updated on 4/20/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vizimpro (Dacomitinib) Prescribing Information.2018Pfizer Inc., New York, NY